-
Uncategorized2 weeks ago
Oryon Splashes Onto Parkinson’s Scene With $42M for Cell Therapy
Oryon Cell Therapies’ lead cell therapy is an autologous treatment designed to replace dopaminergic neurons in patients with Parkinson’s disease. Phase 1b/2a data showed that the...
-
Uncategorized2 weeks agoCollaboration to advance precision oncology therapy
Oncology company One-carbon Therapeutics has entered a strategic collaboration with precision medicine company Tempus AI to advance precision oncology development. The collaboration will leverage Tempus’ proprietary,...
-
Uncategorized2 weeks agoIsomAb appoints CEO to lead development of angina treatment
Biotechnology company IsomAb has appointed Dr Philip Brainin as Chief Executive Officer as it looks to enter clinic with a treatment for chronic stable angina (CSA). ...
-
Uncategorized2 weeks agoClot-busting drug could harm stroke treatment response
A clot-busting drug may stop promising stroke medicine from working properly, research reveals. Researchers at the University of Manchester found the clot-busting therapy, known as tissue...
-
Uncategorized2 weeks ago
Validated Mechanisms, Strong Data Beat Hype in Longevity Investing
Longevity is a long-standing buzzword in life sciences, but it now has staying power. The smart trajectory is to stop chasing aging as an abstract target...
-
Uncategorized2 weeks ago
Powering the Next Wave of Cell Therapy: From iPSC-Derived Cells to In Vivo Reprogramming
As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and manufacturing-ready reagent platforms are reshaping regenerative medicine and oncology. Recombinant antibodies...
-
Uncategorized2 weeks ago
Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality
Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential billion-dollar market and banking on...
-
Uncategorized2 weeks ago
9 Months In, FDA’s New Priority Voucher Program Still Clouded With Uncertainty
The FDA’s Commissioner’s National Priority Voucher program, unveiled in June 2025, is “shrouded in secrecy,” Democratic representative Jake Auchincloss said last month, as regulatory and biopharma...
-
Uncategorized3 weeks ago
Gossamer, BiomX Reveal Hefty Staff Cuts
Follow along as BioSpace tracks job cuts and restructuring initiatives.
-
Uncategorized3 weeks ago
HHS Denies Disbandment of CDC Vaccine Advisory Group in Wake of Court Ruling
A spokesperson for the Department of Health and Human Services refuted the claim, made Thursday on social media by ACIP Vice Chair Robert Malone, calling it...
BioNTech to shutter Singapore HQ after ‘comprehensive review’
STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
